russian pharmaceutical market 2012

RussianPharmaceutical Market

2012

15 April 2013Shulyak SergeyGeneral DirectorDSM Group

The result of 2012 year

Source: DSM Group, audit of pharmaceutical market RF

The result of 2012 year: units

Source: DSM Group, audit of pharmaceutical market RF

Per capita consumption of medicines in Russia(pharma market)

Source: DSM Group, audit of pharmaceutical market RF

Retail segment is 74% Russian pharma market

Source: DSM Group, audit of pharmaceutical market RF

Retail segment in recent years, growing much faster

Source: DSM Group, audit of pharmaceutical market RF

Turnover of drags market is positive in EURO

Source: DSM Group, audit of pharmaceutical market RF

The largest contribution to the growth of pharma market - structural change in favor of expensive drugs

Source: DSM Group, audit of pharmaceutical market RF

Retail drug market capacity in Russia and other countries in 2012

Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources

Retail drug market capacity in Russia and other countries in 2012

Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources

Per capita consumption of medicines in the world(retail drug market)

Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources

Rating of drug manufacturing companies:TOP 20 – 52,5%

Source: DSM Group, audit of pharmaceutical market RF

Sales value, million $.

2012

1 - NOVARTIS 1 365,9 -4,7% 5,5%2 - SANOFI 1 297,5 0,6% 5,2%3 - PHARMSTANDART 892,9 -4,3% 3,6%4 - F.HOFFMANN-LA ROCHE 766,3 4,6% 3,1%5 - TEVA PHARMACEUTICAL 739,9 1,3% 3,0%6 1 TAKEDA 716,8 10,6% 2,9%7 4 ABBOTT 702,9 26,8% 2,8%8 - BAYER 667,4 -3,3% 2,7%9 3- BERLIN-CHEMIE 667,4 6,5% 2,7%10 - MERCK 586,0 1,6% 2,4%11 2 PFIZER 566,2 12,4% 2,3%12 3- GEDEON RICHTER 563,9 -3,4% 2,3%13 1- GLAXOSMITHKLINE 546,0 5,2% 2,2%14 - SERVIER 505,8 2,2% 2,0%15 - JANSSEN PHARMACEUTICA 494,8 2,4% 2,0%16 2 STADA 428,6 8,0% 1,7%17 1- BOEHRINGER INGELHEIM 428,3 5,9% 1,7%18 1 KRKA 421,7 6,6% 1,7%19 2- ASTRAZENECA 363,5 -8,7% 1,5%20 - ASTELLAS PHARMA 351,3 20,7% 1,4%

2012 Ranking

Change Manufacturer Growth Share

Rating of ATC classification

Source: DSM Group, audit of pharmaceutical market RF

ATC level 2 Share, $

J 01 ANTIBACTERIALS FOR SYSTEMIC USE 7,0%

L01 ANTINEOPLASTIC AGENTS 6,0%

L03 IMMUNOMODULATING AGENTS 4,1%

J 05 ANTIVIRALS FOR SYSTEMIC USE 3,9%

M01 ANTI INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 3,0%

ATC level 2 Share, units

N02 ANALGESICS 10,2%

J 01 ANTIBACTERIALS FOR SYSTEMIC USE 9,3%

B05 PLASMA SUBSTITUTES AND PERFUSION SOLUTIONS 7,0%

D08 ANTISEPTICS AND DISINFECTANTS 5,1%

R01 NASAL PREPARATIONS 4,3%

Quantity of drugs in the Russian pharma market

Source: DSM Group, audit of pharmaceutical market RF

QuantityRetail segment of medicines

Segment of health care institutions

Reimbursement program

Pharma market

The full name of the drug (SKU) 22 572 15 953 5 271 27 242

The trade name of the drug 6 916 5 616 2 349 7 700

The brand name of the drug 4 769 4 179 1 804 5 368

INN 1 914 1 803 802 2 053

The drug manufacturing company 1 087 873 450 1 191

www.dsm.ru

JSC “DSM Group”Yamskogo Polya St. 7/2

Moscow, 125040Russia

Contacts:

Sergey Shulyak sshulyak@dsm.ruLilit Kotsinyan lkotsinyan@dsm.ru